Altimmune Inc.
(NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial assessing pemvidutide in patients diagnosed with moderate to severe alcohol use disorder (AUD).
The late clinical-stage biopharmaceutical company confirmed that the study successfully met its primary endpoint, showing a statistically significant decrease in heavy drinking days per week compared to placebo.
Read Also: EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disorder Worth Up To $60 Million Efficacy Metrics And Weight Loss Data The investigational candidate—a balanced glucagon/GLP-1 dual receptor agonist—also achieved statistically significant improvements across major secondary endpoints, including two registrational endpoints.
Results demonstrated a two-level reduction in World Health Organization Risk Drinking Levels, an increased incidence of zero heavy drinking days, a higher percentage of days with total abstinence, and reduced phosphatidyl ethanol (PEth) levels versus placebo.
